Mirae Asset Healthcare Fund
The scheme seek to generate long term capital appreciation through investing in equity and equity related securities of companies/Entities benefitting directly or indirectly in Healthcare and allied sectors in India.
Growthvine rating: 4/5 — ranked #13 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹45.09 (as of 2026-10-01) |
|---|
| AUM | ₹3,442 Cr |
|---|
| Expense ratio | 1.65% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Tanmay Mehta |
|---|
| Exit load | 1% for redemption within 1 month |
|---|
Performance & risk
| 5-year annualised return | 13.64% |
|---|
| Sharpe ratio | 0.98 |
|---|
| Standard deviation | 16.11% |
|---|
| Max drawdown | −20.09% |
|---|
| Alpha | -0.74 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 95.1% of NIFTY Pharma's upside and 90.0% of its downside.
Market cap allocation
| Large cap | 36.6% |
|---|
| Mid cap | 42.6% |
|---|
| Small cap | 20.8% |
|---|
Concentration
| Top 5 holdings | 39.0% |
|---|
| Top 10 holdings | 58.6% |
|---|
| Total holdings | 29 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 10.9%
- Divis Laboratories Ltd. — 9.9%
- Torrent Pharmaceuticals Ltd. — 7.1%
- Apollo Hospitals Enterprises Ltd. — 5.9%
- Laurus Labs Limited — 5.2%
- Glenmark Pharmaceuticals ltd — 5.0%
- Dr. Reddys Laboratories Ltd. — 3.9%
- Aurobindo Pharma Ltd. — 3.8%
- Ipca Laboratories Ltd. — 3.4%
- Fortis Healthcare Ltd — 3.4%
Top sectors
- Pharma & Biotech — 75.4%
- Healthcare — 23.2%
- Chemicals — 1.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 18.0% | Q1 (Top) | #8 of 76 |
| 2025 | −3.4% | Q3 | #47 of 69 |
| 2024 | 39.1% | Q1 (Top) | #12 of 58 |
| 2023 | 34.0% | Q3 | #29 of 48 |
| 2022 | −11.8% | Q4 (Bottom) | #39 of 46 |